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ABSTRACT
Objectives To assess the acceptability of 
neuromuscular electrical stimulation (NMES) of the 
quadriceps muscles in people with idiopathic pulmonary 
fibrosis (IPF) and to identify whether a future definitive 
trial is feasible.
Design A randomised, parallel, two- group, participant and 
assessor- blinded, placebo- controlled feasibility trial with 
embedded qualitative interviews.
Setting Outpatient department, Royal Brompton and 
Harefield Hospitals.
Participants Twenty- two people with IPF: median (25th, 
75th centiles) age 76 (74, 82) years, forced vital capacity 
62 (50, 75) % predicted, 6 min walk test distance 289 
(149, 360) m.
Interventions Usual care (home- based exercise, weekly 
telephone support, breathlessness management leaflet) 
with either placebo or active NMES for 6 weeks, with 
follow- up at 6 and 12 weeks.
Primary outcome measures Feasibility of recruitment 
and retention, treatment uptake and adherence, outcome 
assessments, participant and outcome assessor blinding 
and adverse events related to interventions.
Secondary outcome measures Outcome measures 
with potential to be primary or secondary outcomes in a 
definitive clinical trial. In addition, purposively sampled 
participants were interviewed to capture their experiences 
and acceptability of the trial.
Results Out of 364 people screened, 23 were recruited: 
11 were allocated to each group and one was withdrawn 
prior to randomisation. Compared with the control 
group, a greater proportion of the intervention group 
completed the intervention, remained in the trial blinded 
to group allocation and experienced intervention- related 
adverse events. Assessor blinding was maintained. The 
secondary outcome measures were feasible with most 
missing data associated with the accelerometer. Small 
participant numbers precluded identification of an outcome 
measure suitable for a definitive trial. Qualitative findings 
demonstrated that trial process and active NMES were 
acceptable but there were concerns about the credibility of 
placebo NMES.
Conclusions Primarily owing to recruitment difficulties, a 
definitive trial using the current protocol to evaluate NMES 
in people with IPF is not feasible.
Trial registration number NCT03499275.
INTRODUCTION
Idiopathic pulmonary fibrosis (IPF) is char-
acterised by progressive dyspnoea, reduction 
in functional capacity and subsequent loss of 
independence.1 2 Several factors contribute 
to this, including declining lung function 
and peripheral muscle weakness.3 There is 
growing interest in the latter, as it is known that 
people with IPF have smaller rectus femoris 
cross- sectional area4 as well as reduced quad-
riceps strength3–5 and endurance5 compared 
with matched healthy controls.
The National Institute for Health and 
Care Excellence (NICE) recommends 
regular assessment for and offering pulmo-
nary rehabilitation (PR) to people with IPF.6 
However, people with advanced disease and 
severe breathlessness may have difficulties 
Strengths and limitations of this study
 ► This is the first study to examine the feasibility of 
neuromuscular electrical stimulation in people with 
idiopathic pulmonary fibrosis.
 ► The intervention was developed using a combination 
of patient and public involvement feedback and pre-
viously published studies.
 ► We blinded the outcome assessor to group alloca-
tion and used an existing placebo neuromuscular 
electrical stimulator device to blind participants in 
the control group.
 ► We conducted qualitative interviews to capture par-
ticipant experiences.
 ► The study took place at a single site and may have 
been a limiting factor for participant recruitment.
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undertaking PR as ventilatory limitation may preclude 
effective whole body training.7 Centre- based PR or exer-
cise programme completion rates range from 43%8 
to 94%.9 People with more severe disease and those 
unwilling to participate in group programmes are less 
likely to complete these programmes.10 Accordingly, 
home- based ways of conferring the benefits of exercise 
are required.
Guidance from NICE states that in people not suit-
able for, or unable to participate in, existing rehabilita-
tion programmes, neuromuscular electrical stimulation 
(NMES) of the quadriceps offers an alternative means of 
enhancing muscle strength.11 NMES uses a small battery- 
operated stimulator which, via surface electrodes placed 
on the anterior thigh, produces a controlled contraction 
and relaxation of the underlying muscles. It is safe, rela-
tively inexpensive and is performed seated at home. In 
people with advanced chronic disease including chronic 
obstructive pulmonary disease, heart failure and cancer, a 
meta- analysis demonstrated that compared with placebo, 
NMES led to a significant improvement in quadriceps 
strength, muscle mass and exercise capacity.12 Therefore, 
NMES may be a potential treatment for muscle weakness 
in advanced progressive disease and could be considered 
a suitable home intervention for people with muscle 
weakness who have difficulty engaging with existing 
PR services.11 12 To date, there are no published studies 
exploring the role or effects of NMES in IPF, although 
there is one small randomised controlled trial (n=30) 
comparing active NMES plus aerobic exercise to placebo 
NMES plus aerobic exercise that is currently recruiting 
people with IPF (NCT03890250). Therefore, we aimed to 
determine the acceptability of NMES of the quadriceps in 
people with IPF and to identify whether a future defini-
tive trial is feasible.
MATERIALS AND METHODS
Study design and participants
We conducted a randomised, parallel, two- group, partic-
ipant and assessor- blinded, placebo- controlled feasibility 
trial with embedded qualitative interviews. The trial 
was conducted and reported according to the Consoli-
dated Standards of Reporting Trials (CONSORT) 2010 
statement: extension to randomised pilot and feasibility 
trials.13 Participants were recruited from outpatient 
clinics at the Royal Brompton and Harefield Hospitals, 
UK, between November 2018 and February 2020. The 
inclusion criteria were (1) diagnosis of IPF according to 
international guidelines,14 (2) Medical Research Council 
(MRC) dyspnoea score ≥3, (3) quadriceps maximum 
voluntary contraction (QMVC) <80% predicted,15 (4) 
declined or failed to complete supervised centre- based 
PR, and (5) ability to provide informed consent. People 
were excluded for the following reasons: (1) cardiac 
pacemaker, (2) coexisting neurological condition, for 
example, lower limb paralysis, (3) completion of PR 
within the previous 6 months, (4) change in medication 
and/or exacerbation requiring hospitalisation within 
the previous 4 weeks, or (5) current regular exerciser 
(structured exercise ≥3/week in the previous month). All 
participants provided written informed consent. The trial 
was pre- registered on  ClinicalTrials. gov.
Randomisation and blinding
Following baseline assessment, participants were 
randomly allocated 1:1 at the individual level to receive 
active or placebo NMES. Minimisation was used to 
balance groups for age (<65 years vs ≥65 years), sex (male 
vs female) and quadriceps strength (<20 kg vs ≥20 kg). 
The allocation sequence was generated using an inde-
pendent web- based randomisation system within the 
UK Clinical Research Collaboration- registered King’s 
Clinical Trials Unit. Following randomisation, the Clin-
ical Trials Unit informed trial staff by secure email. An 
unblinded researcher selected an active or placebo device 
accordingly. Blinded researchers were informed of trial 
entry but not group allocation. The participant was not 
informed of group allocation. Subsequent assessment 
visits were completed immediately after the 6- week inter-
vention period and at 12 weeks by a researcher blinded to 
group allocation. Qualitative in- depth, topic- guided inter-
views were completed in a subgroup of participants who 
were selected purposively to include both intervention 
and control groups, sexes and a range of baseline MRC 
scores so that different perspectives could be explored.
Interventions
The treating healthcare professionals provided potential 
participants with the study information leaflet who were 
then screened by the research team via telephone. Those 
interested in participating in the study attended an assess-
ment to confirm eligibility.
The interventions were based on a combination of 
patient and public involvement (PPI) feedback and 
published studies.16 The NMES programme was a self- 
administered, home- based protocol involving 30 min stim-
ulation of bilateral quadriceps muscles for 6 weeks. The 
active device was KneeHab XP (Neurotech, USA) and the 
placebo device was MicroStim Exercise Stimulator MS2v2 
(Odstock Medical, UK). Although different machines 
were used for the active and placebo devices, they were 
outwardly identical as both were covered in the same 
garment (online supplemental file). The parameters of 
both devices were the same (frequency 50 Hz, pulse width 
400 μs, duty cycle 18%–33% which increased weekly for 
the first 3 weeks) except for the amplitude range (active: 
0–120 mA; placebo: 0–20 mA). Consequently, partici-
pants in the control group received sensory feedback 
during stimulation but the device did not elicit a tetanic 
muscle contraction.
Participants in both groups also received a leaflet on 
how to manage breathlessness and an individualised 
home exercise programme supplemented with a manual 
which they were instructed to perform at least three times 
per week (online supplemental file).
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The unblinded researcher delivered a standardised 
40 min training session to participants in both groups to 
demonstrate and supervise NMES application and the 
home exercise programme. Participants were provided 
with a diary to record NMES and exercise performance. 
During the 6- week intervention period, the unblinded 
researcher telephoned participants weekly to review and 
progress NMES use and home exercise performance. To 
progress NMES, participants were asked to increase the 




The primary outcomes were related to feasibility: partic-
ipant recruitment and retention, treatment uptake and 
adherence, feasibility of outcome assessments, feasibility 
of participant and assessor blinding and adverse events 
related to the interventions. To assess recruitment and 
retention- related feasibility outcomes, the numbers of 
potential eligible participants as well as recruitment and 
retention rates at the 6 and 12- week assessments were 
recorded. To assess treatment uptake and adherence, 
the following were recorded: feasibility, outcomes, rates 
of uptake of and adherence to the allocated intervention 
and frequency and time spent using the NMES device 
and performing the home exercise programme. Feasi-
bility of outcome assessment was measured by recording 
the amount of missing data for each outcome measure 
at each assessment. Participant and assessor blinding 
was assessed by the unblinded researcher at the 6- week 
assessment, and 6 and 12- week assessments, respectively. 
Research staff recorded adverse events during assessment 
visits and weekly telephone calls. These were classified as 
related or unrelated to the allocated intervention using as 
much information as available to determine the potential 
attribution of the event.
Secondary outcome measures
The secondary outcome measures were those that had 
the potential to be primary or secondary outcomes in 
a definitive clinical trial. These were: exercise capacity 
(6 min walk test),17 functional performance (Short Phys-
ical Performance Battery),18 4 m gait speed,19 rectus 
femoris size (ultrasound of rectus femoris cross- sectional 
area (Mindray DP-50, Caiyside Imaging, Scotland)), 
quadriceps strength (isometric QMVC),20 health- related 
quality of life (King’s Brief Interstitial Lung Disease ques-
tionnaire),21 activities of daily living (London Chest Activ-
ities of Daily Living questionnaire)22 and physical activity 
parameters (daily step count, time spent sedentary, light 
and moderate- intensity activity (SenseWear, BodyMedia, 
USA)).23
Following the 12- week assessment, purposively sampled 
participants were invited to take part in semistruc-
tured, topic- guided, telephone- based interviews. The 
audio- recorded interviews explored experiences of the 
intervention, how it impacted perceptions of outcome, 
acceptability of outcome measures and trial conduct in 
order to inform the rationale for and conduct of a defin-
itive trial. The topic guides were updated inductively 
to reflect experiences and perceptions raised during 
previous interviews.
Sample size
Sample size estimation was performed to achieve the 
primary feasibility outcomes, and not to detect differences 
in the secondary outcome measures. Based on guidance 
in the literature, we estimated that a sample size of 60 (30 
per group) would be sufficient to adequately evaluate the 
feasibility of undertaking a definitive trial. A sample size 
of 10 was chosen for the qualitative interviews as it was 
based on the predicted minimum number of interviews 
required to achieve data saturation and is based on the 
concept of information power.24
Statistical analysis
The feasibility outcomes and baseline demographics were 
described and summarised overall and by trial group 
using proportions (percentage) or median (25th, 75th 
centiles). The baseline data and change at 6 and 12 weeks 
were reported as median (25th, 75th centiles) or median 
(25th, 75th centiles) change for each trial group.
Anonymised interview transcripts were transcribed 
verbatim and imported into NVivo (QSR International, 
Australia) to facilitate analysis using the framework 
method.25 The coding frame was predefined and included 
experiences of the interventions, impact of intervention 
on perceived outcome, acceptability and experiences of 
trial conduct and acceptability of the outcome measures. 
During indexing, secondary codes were inductively 
applied. A mixed methods matrix26 of qualitative and 
key quantitative data was used to illuminate barriers and 
facilitators for intervention completion by participants to 
inform protocol adaptation and/or optimisation.
Patient and public involvement
This research has included PPI throughout each stage. 
Two PPI representatives were involved in the design of 
the study and intervention and met the project manager 
at regular intervals throughout the study. The PPI repre-
sentatives also provided input into written material for 
participants and topic guides for qualitative interviews. 
Going forward, they will have a role in dissemination of 
research findings to lay audiences.
RESULTS
Primary outcome
Feasibility of recruitment and retention
We screened 364 people, of whom 153 were assessed for 
eligibility and 23 consented to participate in the study: 
11 were allocated to both the intervention and control 
groups and one was withdrawn prior to randomisation for 
safety reasons (figure 1). By far, the most common reason 
for failing the telephone- based screening assessment was 
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the distance participants were required to travel to the 
research centre (n=153). MRC<3 (n=55) or PR comple-
tion within 6 months (n=24) were the most common 
reasons for failing the eligibility assessment. At the 6- week 
assessment, two participants in both groups were lost to 
follow- up (intervention: n=2 missed visit, control: n=2 
withdrew from the study). At the 12- week assessment, 
all participants in the intervention group were assessed 
whereas three participants in the control group were lost 
to follow- up (withdrew from the study).
Feasibility of treatment uptake and adherence
All participants started their allocated intervention. Both 
groups received the same median number of weekly tele-
phone calls but there was a trend for higher frequency 
and duration of use of the NMES device and home 
Figure 1 Consolidated Standards of Reporting Trials (CONSORT) diagram. IPF, idiopathic pulmonary fibrosis; MRC, Medical 
Research Council; PR, pulmonary rehabilitation; QMVC, quadriceps maximum voluntary contraction.
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exercise programme in the intervention compared with 
the control group (table 1). All participants in the inter-
vention group completed the allocated intervention. In 
contrast, four participants in the control group discon-
tinued the intervention: n=2 did not tolerate placebo 
NMES, n=1 unwell, n=1 felt NMES was ineffective.
Feasibility of outcome assessment
Missing data for each clinical outcome according to 
assessment time point are described in the online supple-
mental file. There were no missing data at the baseline 
assessment. Missing data at the 6 and 12- week assessments 
mostly related to participants that were lost to follow- up. 
The outcome measures with the most missing data were 
the physical activity parameters (intervention, control: 
baseline: n=4, n=4; 6 and 12 weeks: n=5, n=6). Reasons 
for missingness included participants declining to wear 
the device and insufficient data to analyse.
Feasibility of participant and outcome assessor blinding
Participant blinding was maintained in the intervention 
group but three participants in the control group were 
unblinded as they did not believe the placebo NMES 
was credible. The outcome assessor remained blinded to 
intervention allocation of all participants.
Adverse and serious adverse events
There was one serious adverse event in the intervention 
group and four in the control group. None of these 
events were unexpected or related to the allocated inter-
vention or assessments. One participant experienced 
two adverse events prior to randomisation. A total of 10 
and five adverse events in the intervention and control 
groups were experienced by eight and four participants, 
respectively. None of the events prior to randomisation 
or in the control group were unexpected or related to 
the study. Three adverse events in the intervention group 
were expected and related to the study. These included 
redness on anterior thigh and itchiness on anterior thigh 
following NMES use as well as ‘burning sensation’ on 
anterior thigh during NMES use. The remaining seven 
adverse events were expected and unrelated to the 
intervention.
Secondary outcomes
The groups were balanced in terms of age, gender, 
absolute and relative forced vital capacity values, body 
mass index and quadriceps strength (table 2). However, 
compared with the intervention group, the control group 
had a greater proportion of participants diagnosed with 
pulmonary hypertension, prescribed supplementary 
oxygen and corticosteroid, former smokers and worse 
absolute and relative diffusing capacity of the lung for 
carbon monoxide (DLCO) values, exercise capacity, activ-
ities of daily life performance, walking speed and physical 
activity levels. Due to the small number of participants in 
each group, it was not possible to test for between- group 
differences.
The response to the intervention between baseline and 
6- week assessment, and baseline and 12- week assessment 
is shown in tables 3 and 4, respectively. Again, owing to 
the small numbers of participants, it is not possible to 
draw firm conclusions from these data. However, between 
the baseline and 6- week assessment, there was a trend 
for a greater reduction in sedentary time in the inter-
vention group, compared with an increase in sedentary 
time in the control group (table 3). Similarly, between the 
baseline and 12- week assessment, there was a trend for 
a greater increase in rectus femoris cross- sectional area, 
self- care related to activities of daily living performance 
and time spent in light- intensity physical activity in the 
intervention compared with the control group (table 4).
Six participants (four male, two female), aged between 
54 and 84 years, participated in the qualitative interviews. 
The majority had been allocated to the intervention 
group, with only one participant from the control group. 
Other participants allocated to the control group who 
were approached to take part in the interviews declined 
or were unable to take part because of illness or death. 
Despite interviewing almost one- third of participants who 
were recruited to the trial, new data were being gained up 
to and including the last interview.
All participants found the research staff, trial processes 
and outcome measures acceptable:
I was able to comply with what was required,…, other 
than the fact that the walking is limited, but at least I 
could rest. (Male, 80s, intervention group)
Table 1 Intervention uptake, adherence and completion
Variable Intervention Control
Number of weekly telephone calls 6 (5, 6) 6 (4, 6)
Number of times device* used between V1 and V2 31 (22, 44) 24 (4, 40)
Total minutes device* used between V1 and V2 930 (660, 1110) 570 (120, 1230)
Number of times HEP performed between V1 and V2 20 (17, 32) 14 (4, 26)
Total minutes HEP performed between V1 and V2 906 (600, 1527) 648 (110, 1399)
Data reported number or median (25th, 75th) centile.
*Device: intervention group: active stimulator; control group: placebo stimulator.
HEP, home exercise programme; V, visit.
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Table 2 Baseline characteristics
Whole group (n=22) Intervention (n=11) Control (n=11)
Gender: male (%) 16 (73) 7 (64) 8 (73)
Age (years) 76 (74, 82) 77 (73, 81) 76 (74, 84)
MRC dyspnoea score 4 (4, 4) 4 (4, 4) 4 (4, 4)
BMI (kg/m2) 24.4 (22.4, 29.1) 24.2 (22.0, 26.5) 25.2 (22.6, 29.2)
FEV1/FVC 0.84 (0.78, 0,86) 0.80 (0.77, 0,85) 0.84 (0.78, 0,87)
FVC (L) 1.83 (1.39, 2.44) 1.83 (1.44, 2.45) 1.82 (1.22, 2.44)
FVC (% predicted) 61.8 (49.8, 75.0) 63.0 (49.0, 78.2) 60.5 (50.0, 68.0)
DLCO (mL/min/mm Hg) 2.16 (1.71, 2.77) 2.50 (1.92, 3.36) 1.88 (1.64, 2.20)
DLCO (% predicted) 26.0 (21.9, 36.7) 36.5 (22.3, 40.4) 25.0 (20.8, 29.8)
Smoking status: never/former/current (%) 13 (59)/9 (41)/0 (0) 7 (64)/4 (36)/0 (0) 6 (55)/5 (45)/0 (0)
Smoking pack- year history 0 (0, 8) 0 (0, 5) 0 (0, 13)
Age- adjusted Charlson Comorbidity Index 2 (0, 5) 4 (0, 5) 0 (0, 6)
COPD, n (%) 3 (14) 1 (10) 2 (18)
Pulmonary hypertension, n (%) 2 (9) 0 (0) 2 (18)
Ischaemic heart disease, n (%) 8 (36) 5 (46) 3 (27)
Obstructive sleep apnoea, n (%) 0 (0) 0 (0) 0 (0)
Self- reported hospitalisations in previous year, n (%) 0 (0, 0) 0 (0, 0) 0 (0, 0)
Self- reported chest infections in previous year, n (%) 1 (1, 2) 1 (1, 2) 1 (1, 1)
Oxygen, n (%)
  Long term 4 (18) 1 (10) 3 (27)
  Ambulatory 9 (41) 4 (36) 5 (46)
Walking aid, n (%) 5 (23) 2 (18) 3 (27)
Prescribed pirfenidone, n (%) 6 (27) 4 (36) 2 (18)
Prescribed nintedanib, n (%) 7 (32) 4 (36) 3 (27)
Prescribed corticosteroid, n (%) 4 (18) 3 (27) 1 (9)
6MWT (m) 289 (149, 360) 326 (150, 361) 240 (130, 325)
SPPB score 9 (6, 11) 10 (6, 11) 7 (4, 11)
Four- metre gait speed (m/s) 0.71 (0.50, 0.94) 0.82 (0.38, 0.97) 0.66 (0.51, 0.84)
QMVC (kg) 22.4 (15.6, 28.7) 22.5 (15.1, 28.3) 22.4 (15.7, 31.3)
QMVC (% predicted) 62.4 (52.0, 69.1) 64.3 (44.0, 68.1) 61.6 (52.8, 72.2)
Rectus femoris cross- sectional area (mm2) 459 (371, 534) 451 (321, 579) 479 (375, 581)
KBILD—psychological 54.4 (53.2, 69.1) 58.8 (41.2, 71.6) 53.5 (43.8, 65.5)
KBILD—breathlessness and activities 35.6 (21.6, 45.9) 37.8 (27.0, 50.2) 35.6 (17.7, 41.9)
KBILD—chest symptoms 68.6 (44.0, 85.2) 63.7 (44.0, 85.2) 73.4 (54.3, 85.2)
KBILD—total score 53.5 (46.4, 59.4) 56.1 (43.9, 66.4) 53.5 (47.2, 56.1)
LCADL—self- care 6.0 (4.0, 8.0) 7.0 (4.0, 8.0) 6.0 (4.0, 7.0)
LCADL—domestic 10.5 (4.8, 18.5) 5.0 (1.0, 17.0) 14.0 (10.0, 22.0)
LCADL—physical 4.0 (3.0, 6.0) 4.0 (3.0, 5.0) 4.0 (3.0, 6.0)
LCADL—leisure 4.0 (3.0, 6.0) 4.0 (3.0, 6.0) 5.0 (4.0, 6.0)
LCADL—total score 26.0 (17.5, 37.3) 20.0 (14.0, 28.0) 33.0 (22.0, 29.0)
Daily step count 1511 (776, 3456) 1820 (1148, 3232) 988 (657, 4115)
Daily minutes spent in moderate- intensity PA 34 (20, 84) 47 (25, 100) 22 (5, 74)
Daily minutes spent in light- intensity PA 194 (147, 221) 217 (126, 248) 187 (153, 199)
Daily minutes spent sedentary 1144 (1098, 1206) 1123 (1095, 1151) 1194 (1137, 1237)
Data reported as number (percentage) or median (25th centile, 75th centile).
KBILD domains and total score: range 0–100; higher scores indicate better health- related quality of life.
LCADL range: self- care: 0–20; domestic: 0–30; physical: 0–10; leisure: 0–15; total: 0–75; higher scores indicate greater impact on activities of daily living (ADL) 
performance.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; DLCO, diffusing capacity of the lung for carbon monoxide; FEV1, forced expiratory volume in 1 
s; FVC, forced vital capacity; KBILD, King’s Brief Interstitial Lung Disease questionnaire; LCADL, London Chest Activities of Daily Living questionnaire; MRC, Medical 
Research Council; 6MWT, 6 min walk test; PA, physical activity; QMVC, quadriceps maximum voluntary contraction; SPPB, Short Physical Performance Battery.
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Most participants stated that the NMES device was 
feasible and acceptable:
The instructions were pretty straightforward, and 
once you have done it the first time,…, you just got it 
out of the bag and off you went. (Male, 80s, interven-
tion group)
However, two participants reported negative NMES 
experiences:
It was a damn nuisance, to be perfectly frank,…, no, 
it was a bit of a performance and a bit of a nuisance. 
(Female, 70s, intervention group)
It was as if it was a placebo in place of the real thing,…, 
yes, I would say that it was the placebo, it wasn't the 
real thing. (Male, 70s, control group)
All participants reported that the exercise programme 
was feasible, acceptable and beneficial:
I’m still doing them, actually. It’s a good programme. 
(Female, 70s, intervention group)
However, maintaining motivation to complete the 
programme was difficult with one participant stating that 
he did so because it was part of the study:
I made sure I did the leg exercises [even when un-
well] because that’s what I promised I would do. 
(Male, 60s, intervention group)
There was disparity in participants’ experience of the 
weekly telephone support during the 6- week intervention 
period. Some found it burdensome and suggested that 
digital monitoring would have been preferable:
That [provision of electronic version of home exer-
cise programme] would have better. Yes, that would 
have been brilliant, and to then send it [diary re-
porting compliance and progress] back that way too. 
(Female, 70s, intervention group)
In contrast, other participants found it to be a positive 
experience and suggested more frequent monitoring 
would have been preferable:
I think once a week, or maybe twice a week would be 
a secondary call, if you did it on a Monday and then 
on a Friday. (Male, 60s, intervention group)
In addition, some participants reported that diary 
completion was difficult which affected their compliance 
with this tool:




n Within- group difference n Within- group difference
∆ 6MWT (m) 9 6 (−16, 45) 8 −17 (−74, 4)
∆ SPPB 9 0 (−1, 1) 8 0 (0, 0)
∆ Four- metre gait speed (m/s) 9 0.03 (0.01, 0.06) 8 −0.04 (−0.09, 0.03)
∆ QMVC (kg) 9 −0.1 (−1.9, 2.5) 8 −0.2 (−1.7, 2.0)
∆ Rectus femoris cross- sectional area (mm2) 9 18.0 (−32.6, 48.3) 8 16.0 (−50.6, 33.0)
∆ KBILD—psychological 9 5.9 (−3.4, 12.8) 9 0 (−7.2, 9.6)
∆ KBILD—breathlessness and activities 9 9.3 (−7.8, 13.8) 9 0 (−8.4, 13.5)
∆ KBILD—chest symptoms 9 9.7 (−5.9, 16.7) 9 9.7 (−5.9, 22.9)
∆ KBILD—total score 9 2.7 (−0.2, 7.4) 9 0.1 (−2.2, 3.9)
∆ LCADL—self- care 9 −1.0 (−2.0, 0.0) 9 1.0 (−0.5, 1.5)
∆ LCADL—domestic 9 1.0 (−3.0, 4.5) 9 −1.0 (−3.0, −5.0)
∆ LCADL—physical 9 0.0 (−0.5, 0.5) 9 0.0 (−1.0, 1.5)
∆ LCADL—leisure 9 0.0 (−1.0, 1.0) 9 0.0 (−1.0, 1.5)
∆ LCADL—total score 9 0.0 (−5.0, 2.0) 9 4.0 (−3.0, 10.0)
∆ Daily step count 5 −270 (−504, 877) 5 −740 (−2026, −230)
∆ Daily minutes spent in moderate- intensity PA 5 −3 (−20, 4) 5 −19 (−51, −5)
∆ Daily minutes spent in light- intensity PA 5 24 (5, 71) 5 −39 (−65, 15)
∆ Daily minutes spent sedentary 5 −40 (−58, −21) 5 54 (22, 86)
Data reported as median (25th centile, 75th centile) difference.
KBILD domains and total score: range 0–100; higher scores indicate better health- related quality of life.
LCADL range: self- care: 0–20; domestic: 0–30; physical: 0–10; leisure: 0–15; total: 0–75; higher scores indicate greater impact on activities of 
daily living (ADL) performance.
KBILD, King’s Brief Interstitial Lung Disease questionnaire; LCADL, London Chest Activities of Daily Living questionnaire; 6MWT, 6 min walk 
test; PA, physical activity; QMVC, quadriceps maximum voluntary contraction; SPPB, Short Physical Performance Battery.
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I didn’t fill in the form right. I didn’t find the form 
very easy. I did it my own way. (Female, 70s, interven-
tion group)
DISCUSSION
We aimed to determine the acceptability of NMES of 
the quadriceps muscles in people with IPF and identify 
whether a future definitive trial is feasible. The qual-
itative interviews suggest that participants found the 
trial process, active NMES device and home exercise 
programme acceptable, but there were concerns about 
the credibility of placebo NMES and divergent opinions 
regarding the telephone support and diary. The quanti-
tative data demonstrate that a definitive trial using this 
protocol should not be undertaken because of challenges 
in participant recruitment as well as between- group differ-
ences in retention, treatment adherence and blinding 
of participants in the control compared with the inter-
vention group. However, this feasibility study provided 
important additional information that could inform 
future rehabilitation- based interventions.
Primary feasibility outcomes
The principal reason this protocol in its current format 
should not be tested in a definitive trial is that an insuffi-
cient number of participants were recruited to satisfy the 
a priori sample size requirement. A total of 364 poten-
tial participants were screened with 211 excluded prior 
to the eligibility assessment. The main reason for exclu-
sion was the distance between the person’s home and 
assessment centre, despite the provision of transport. The 
Interstitial Lung Disease Unit at our hospital provides 
specialist care to people who live in a large geographic 
area, which may explain the reluctance to participate in 
the study. Although we have not faced such recruitment 
issues in other studies, our experience with this protocol 
suggests future rehabilitation- based research should be 
multisite and conducted alongside clinical appointments 
and/or located in centres accessible to participants and/
or in participants’ homes. Out of 153 participants who 
attended the eligibility assessment, 23 consented to partic-
ipate in the study. The most common reason for failing 
this assessment was MRC<3 or PR completion within 
6 months. These conditions formed part of the inclusion 
criteria to ensure that people with advanced disease and 




n Within- group difference n Within- group difference
∆ 6MWT (m) 10 −13 (−73, −15) 6 −23 (−100, 18)
∆ SPPB 10 0 (−1, 0) 7 0 (−1, 1)
∆ Four- metre gait speed (m/s) 10 −0.03 (−0.14, 0.08) 7 0.01 (−0.12, 0.09)
∆ QMVC 11 1.0 (−0.9, 4.3) 7 −1.7 (−3.4, 3.7)
∆ Rectus femoris cross- sectional area (mm2) 11 32.6 (2.5, 54.4) 7 −48.6 (−87.8, 10.0)
∆ KBILD—psychological 11 7.8 (4.6, 19.1) 8 4.2 (−4.1, 8.7)
∆ KBILD—breathlessness and activities 11 9.3 (−7.5, 13.6) 8 0 (−10.0, 5.9)
∆ KBILD—chest symptoms 11 10.3 (0, 19.7) 8 10.8 (0, 24.9)
∆ KBILD—total score 11 5.4 (1.1, 8.8) 8 2.6 (−4.1, 4.3)
∆ LCADL—self- care 11 −1.0 (−2.0, 0.0) 8 1.0 (0.3, 2.5)
∆ LCADL—domestic 11 1.0 (−1.0, 3.0) 8 4.0 (−2.5, 9.5)
∆ LCADL—physical 11 0.0 (−1.0, 0.0) 8 0.0 (−1.0, 1.8)
∆ LCADL—leisure 11 0.0 (0.0, 1.0) 8 0.5 (−0.8, 2.8)
∆ LCADL—total score 11 1.0 (−2.0, 5.0) 8 4.5 (0.8, 15.3)
∆ Daily step count 5 −215 (−966, 176) 5 −334 (−2712, 7)
∆ Daily minutes spent in moderate- intensity PA 5 2 (−29, 22) 5 2 (−31, −11)
∆ Daily minutes spent in light- intensity PA 5 37 (−46, 54) 5 −3 (−61, 35)
∆ Daily minutes spent sedentary 5 8 (−29, 87) 5 7 (−24, 50)
Data reported as median (25th centile, 75th centile) difference.
KBILD domains and total score: range 0–100; higher scores indicate better health- related quality of life.
LCADL range: self- care: 0–20; domestic: 0–30; physical: 0–10; leisure: 0–15; total: 0–75; higher scores indicate greater impact on activities of 
daily living (ADL) performance.
KBILD, King’s Brief Interstitial Lung Disease questionnaire; LCADL, London Chest Activities of Daily Living questionnaire; 6MWT, 6 min walk 
test; PA, physical activity; QMVC, quadriceps maximum voluntary contraction; SPPB, Short Physical Performance Battery.
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a sedentary lifestyle respectively were recruited to the 
study. Going forward, trial eligibility based on indication 
for NMES rather than PR completion status may be more 
appropriate.
There was a trend for a greater proportion of partici-
pants in the control group to withdraw from the study, 
discontinue and perform less of the intervention, and/
or become unblinded to group allocation. These findings 
may be related to statistical chance because of the small 
sample size, differences in between- group baseline char-
acteristics and/or poor placebo NMES device credibility. 
The between- group difference in baseline characteris-
tics and concerns about placebo NMES credibility were 
unexpected findings because the minimisation criteria 
used in the randomisation process and the placebo 
device were informed by previous studies.16 Furthermore, 
although two different devices were used to deliver active 
and placebo NMES, the outward appearance of both 
was identical and as such should not have contributed 
to the differences in participant perception. However, 
qualitative findings demonstrated that a participant in 
the control group believed he used a placebo device as 
the sensation was insufficiently strong. However, as only 
one participant allocated to the control group agreed to 
participate in the qualitative interviews, it is unclear if this 
finding is generalisable. Future research should consider 
reviewing the intensity and/or individualise the intensity 
of the placebo device.
In contrast to the control group, qualitative findings 
demonstrated that active NMES was acceptable to partic-
ipants in the intervention group. In addition, the home 
exercise programme was also acceptable to both groups. 
However, there was a difference of opinion regarding 
the frequency of the telephone support and utility of the 
NMES and exercise diary. Exploration of these aspects of 
the intervention is important for future home- based reha-
bilitation studies in IPF.
Although blinding of some participants was not main-
tained, assessor blinding was successful. This was achieved 
by provision of an office isolated from the research labo-
ratory that allowed the unblinded researcher to inform 
participants of group allocation, deliver the training 
session and schedule telephone calls.
The majority of the outcome measures were accept-
able to participants and feasible to perform. However, 
there were a significant volume of missing accelerometer 
data because participants declined to wear the device or 
there were insufficient data to analyse. Going forward, 
researchers may decide to make wearing the device a 
prerequisite to study entry, shorten the device- wearing 
time or consider an alternative device that is more accept-
able to participants.
There was a difference in the amount of expected and 
related adverse events in the intervention compared 
with the control group. These events occurred during or 
following NMES use and did not result in discontinuation 
of the intervention. Although not categorised as serious, 
these findings reinforce the importance of explaining 
the risks associated with this type of intervention in the 
patient information sheet.
Secondary outcome measures
Although the intervention and control groups were 
balanced in terms of the minimisation variables, there was 
imbalance in important variables that might influence 
exercise and physical activity capacity as a greater propor-
tion of the control group were diagnosed with pulmonary 
hypertension and had a supplementary oxygen prescrip-
tion associated with worse absolute and relative DLCO 
values, exercise capacity, activities of daily life perfor-
mance, walking speed and physical activity levels. This may 
have arisen because of statistical chance given the small 
participant numbers; however, the minimisation variables 
used for randomisation may also have contributed to the 
problem. The minimisation variables (age, gender and 
quadriceps strength) were chosen as they were relevant 
to the population of interest and intervention, and were 
also informed by previous studies.16 However, although 
there is a strong correlation between quadriceps strength 
and exercise capacity (r=0.56, p<0.001) in interstitial 
lung disease,27 accounting for exercise capacity itself, as 
well as comorbidities and physical activity levels may be 
important in ensuring balance between trial groups in 
future research.
Owing to the small sample size, imbalance in between- 
group baseline characteristics and smaller number of 
control versus intervention group participants, it is chal-
lenging to identify an outcome measure that has the 
potential to be a primary or secondary outcome measure 
in a definitive trial. However, as there was a trend for 
greater reduction in sedentary time between baseline 
and 6 weeks as well as a greater increase in self- care ability 
and light- intensity physical activity between baseline and 
12 weeks that favoured the intervention group, these 
outcomes may be worth exploring. However, as previously 
discussed, there was a significant amount of missing accel-
erometer data.
Strengths and limitations
There are several strengths to this research. It was 
performed in line with the CONSORT 2010 statement.13 
One of the inclusion criteria was a measure of quadriceps 
strength, which ensured NMES was indicated in the trial 
population. The intervention was based on PPI feedback 
and informed by published trials.16 We used an accepted 
placebo intervention to maintain participant blinding 
with outcomes assessed by a blinded assessor. We tested 
numerous relevant outcome measures that could be used 
in a definitive trial and undertook qualitative interviews 
that complemented the quantitative findings. However, 
there were some limitations. The use of a single centre in 
this trial likely contributed to under- recruitment of partic-
ipants and consequently, we conclude that the current 
protocol should not be used in a definitive trial. This in 
turn led to insufficient recruitment of participants to the 
qualitative aspect, specifically to the control group which 
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is in part a limitation, but also provides initial data on 
feasibility. Consequently, data saturation of experiences 
and perceptions was not achieved. Accordingly, the trans-
ferability of the qualitative findings may be limited.
CONCLUSION
We conclude that a definitive clinical trial to investi-
gate the efficacy of NMES of the quadriceps muscles in 
advanced IPF using this protocol is not feasible. However, 
novel findings such as the frequency of telephone support, 
exercise and NMES diary format and choice of support 
and monitoring platform, for example, online versus tele-
phone, could inform trials of future home rehabilitation 
interventions in this population.
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